

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>PharmAust Limited</b>
<b>ABN</b>	<b>35 094 006 023</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Robert Charles Bishop
<b>Date of last notice</b>	18 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	The securities are held by Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited.  Mr Bishop is the sole shareholder and director of Longbow Croft Capital Pty Ltd and First Capital Markets Pty Limited.
<b>Date of change</b>	2 January 2024
<b>No. of securities held prior to change</b>	9,511,060 Ordinary Fully Paid Shares 150,000 Unlisted Options 30/04/26 – 15c 2,302,766 Listed Options 30/04/2026 – 15c
<b>Class</b>	Unlisted Options 30/04/26 – 15c Listed Options 30/04/2026 – 15c
<b>Number acquired</b>	150,000
<b>Number disposed</b>	150,000
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	
<b>No. of securities held after change</b>	9,511,060 Ordinary Fully Paid Shares 2,452,766 Listed Options 30/04/2026 – 15c
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	As per Appendix 2A lodged on 2 January 2024 and under the Prospectus dated 21 November 2023, the Company sought quotation of the existing 15 cent unlisted Options as they have the same exercise price and expiry date and general terms

+ See chapter 19 for defined terms.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>PharmAust Limited</b>
<b>ABN</b>	<b>35 094 006 023</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Sam Michael Wright
<b>Date of last notice</b>	18 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	The securities are held by Straight Lines Consultancy Pty Ltd as trustee for the Straight Lines Trust. Mr Wright is a Director of Straight Lines Consultancy Pty Ltd and a Beneficiary of the Straight Lines Trust.
<b>Date of change</b>	2 January 2024
<b>No. of securities held prior to change</b>	4,550,000 Ordinary Fully Paid Shares 250,000 Unlisted Options 30/04/26 – 15c 875,000 Listed Options 30/04/2026 – 15c
<b>Class</b>	Unlisted Options 30/04/26 – 15c Listed Options 30/04/2026 – 15c
<b>Number acquired</b>	250,000
<b>Number disposed</b>	250,000
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	
<b>No. of securities held after change</b>	4,550,000 Ordinary Fully Paid Shares 1,125,000 Listed Options 30/04/2026 – 15c
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	As per Appendix 2A lodged on 2 January 2024 and under the Prospectus dated 21 November 2023, the Company sought quotation of the existing 15 cent unlisted Options as they have the same exercise price and expiry date and general terms

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>PharmAust Limited</b>
<b>ABN</b>	<b>35 094 006 023</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Neville John Bassett AM
<b>Date of last notice</b>	18 December 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Shares are held by Mandevilla Pty Ltd. Mr Bassett is a director and shareholder of Mandevilla Pty Ltd.
<b>Date of change</b>	2 January 2024
<b>No. of securities held prior to change</b>	507,000 Ordinary Fully Paid Shares 250,000 Unlisted Options 30/04/26 – 15c 1,750 Listed Options 30/04/2026 – 15c
<b>Class</b>	Unlisted Options 30/04/26 – 15c Listed Options 30/04/2026 – 15c
<b>Number acquired</b>	250,000
<b>Number disposed</b>	250,000
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	
<b>No. of securities held after change</b>	507,000 Ordinary Fully Paid Shares 251,750 Listed Options 30/04/2026 – 15c
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	As per Appendix 2A lodged on 2 January 2024 and under the Prospectus dated 21 November 2023, the Company sought quotation of the existing 15 cent unlisted Options as they have the same exercise price and expiry date and general terms

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
<b>Interest after change</b>	

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

---

+ See chapter 19 for defined terms.